基础科学：病理生理学：心肾代谢综合征 - Suppr

Suppr

超能文献

Basic science: Pathophysiology: the cardiorenal metabolic syndrome.

作者信息

Whaley-Connell Adam, Sowers James R

出版信息

J Am Soc Hypertens. 2014 Aug;8(8):604-6. doi: 10.1016/j.jash.2014.07.003. Epub 2014 Jul 5.

DOI:10.1016/j.jash.2014.07.003

PMID:25151323

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4170524/

Abstract

摘要

相似文献

Basic science: Pathophysiology: the cardiorenal metabolic syndrome.

J Am Soc Hypertens. 2014 Aug;8(8):604-6. doi: 10.1016/j.jash.2014.07.003. Epub 2014 Jul 5.

Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets.

Am J Physiol Heart Circ Physiol. 2017 Oct 1;313(4):H715-H721. doi: 10.1152/ajpheart.00215.2017. Epub 2017 Jul 21.

The management of end-stage heart failure and reducing the risk of cardiorenal syndrome.

Clin Med (Lond). 2013 Dec;13(6):610-3. doi: 10.7861/clinmedicine.13-6-610.

[Cardio-renal syndrome in patients with heart failure: pathophysiology, epidemiology and clinical significance].

Kardiol Pol. 2011;69(11):1181-8.

[Cardiorenal syndrome].

Rev Med Chir Soc Med Nat Iasi. 2011 Jul-Sep;115(3):636-46.

Cardiorenal Syndrome Revisited.

Circulation. 2018 Aug 28;138(9):929-944. doi: 10.1161/CIRCULATIONAHA.117.028814.

Epidemiology of Cardiorenal Syndrome.

Adv Chronic Kidney Dis. 2018 Sep;25(5):391-399. doi: 10.1053/j.ackd.2018.08.009.

[The nephrologist and the role of ultrasound imaging in the diagnosis of cardiorenal syndrome].

G Ital Nefrol. 2012 May-Jun;29(3):321-7.

Cardiorenal syndrome: an evolutionary point of view.

Hypertension. 2012 Sep;60(3):589-95. doi: 10.1161/HYPERTENSIONAHA.111.188706. Epub 2012 Jul 2.

Insulin resistance and heart failure: molecular mechanisms.

Heart Fail Clin. 2012 Oct;8(4):609-17. doi: 10.1016/j.hfc.2012.06.005. Epub 2012 Aug 9.

引用本文的文献

Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.

Circ Res. 2025 May 23;136(11):1454-1475. doi: 10.1161/CIRCRESAHA.125.325517. Epub 2025 May 22.

Cardiovascular-kidney-metabolic Syndrome: a current and urgent concept.

J Bras Nefrol. 2025 Apr-Jun;47(2):e20240277. doi: 10.1590/2175-8239-JBN-2024-0277en.

Joint association of TyG index and LDL-C with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease.

Sci Rep. 2025 Feb 18;15(1):5854. doi: 10.1038/s41598-025-87416-7.

eGFR slope as predictor of mortality in heart failure patients.

ESC Heart Fail. 2025 Apr;12(2):1217-1226. doi: 10.1002/ehf2.15128. Epub 2024 Nov 27.

Cardiovascular-kidney-metabolic syndrome - An integrative review.

Prog Cardiovasc Dis. 2024 Nov-Dec;87:26-36. doi: 10.1016/j.pcad.2024.10.012. Epub 2024 Oct 30.

Insulin Resistance, Hyperinsulinemia and Atherosclerosis: Insights into Pathophysiological Aspects and Future Therapeutic Prospects.

Curr Cardiol Rev. 2025;21(1):e1573403X314035. doi: 10.2174/011573403X314035241006185109.

Impact of inhibition of the renin-angiotensin system on early cardiac and renal abnormalities in Sprague Dawley rats fed short-term high fructose plus high salt diet.

Front Nutr. 2024 Aug 22;11:1436958. doi: 10.3389/fnut.2024.1436958. eCollection 2024.

Heart failure: the grim reaper of the cardio-renal-metabolic triad.

ESC Heart Fail. 2024 Aug;11(4):2334-2343. doi: 10.1002/ehf2.14810. Epub 2024 Apr 24.

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.

Diabetes Ther. 2023 Dec;14(12):1997-2014. doi: 10.1007/s13300-023-01475-5. Epub 2023 Oct 12.

Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases.

Kidney360. 2023 Oct 1;4(10):1382-1388. doi: 10.34067/KID.0000000000000212. Epub 2023 Jul 18.

本文引用的文献

The Role of Overweight and Obesity in the Cardiorenal Syndrome.

Cardiorenal Med. 2011;1(1):5-12. doi: 10.1159/000322822. Epub 2011 Jan 17.

Therapeutic strategies for heart failure in cardiorenal syndromes.

Am J Kidney Dis. 2010 Oct;56(4):759-73. doi: 10.1053/j.ajkd.2010.04.012. Epub 2010 Jun 16.

Prevalence of chronic kidney disease in the United States.

JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038.

Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.

Am J Clin Nutr. 2007 Oct;86(4):899-906. doi: 10.1093/ajcn/86.4.899.

Trends in prevalence and outcome of heart failure with preserved ejection fraction.

N Engl J Med. 2006 Jul 20;355(3):251-9. doi: 10.1056/NEJMoa052256.

Prevalence of overweight and obesity in the United States, 1999-2004.

JAMA. 2006 Apr 5;295(13):1549-55. doi: 10.1001/jama.295.13.1549.

Body mass index and risk for end-stage renal disease.

Ann Intern Med. 2006 Jan 3;144(1):21-8. doi: 10.7326/0003-4819-144-1-200601030-00006.

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.

Am Heart J. 2005 Jan;149(1):54-60. doi: 10.1016/j.ahj.2004.07.009.

Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies.

Ann Epidemiol. 2005 Feb;15(2):87-97. doi: 10.1016/j.annepidem.2004.05.012.

Obesity and the metabolic syndrome in children and adolescents.

N Engl J Med. 2004 Jun 3;350(23):2362-74. doi: 10.1056/NEJMoa031049.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Basic science: Pathophysiology: the cardiorenal metabolic syndrome.

J Am Soc Hypertens. 2014 Aug;8(8):604-6. doi: 10.1016/j.jash.2014.07.003. Epub 2014 Jul 5.

Pathophysiology of cardiorenal syndrome in patients with heart failure: potential therapeutic targets.

Am J Physiol Heart Circ Physiol. 2017 Oct 1;313(4):H715-H721. doi: 10.1152/ajpheart.00215.2017. Epub 2017 Jul 21.

The management of end-stage heart failure and reducing the risk of cardiorenal syndrome.

Clin Med (Lond). 2013 Dec;13(6):610-3. doi: 10.7861/clinmedicine.13-6-610.

[Cardio-renal syndrome in patients with heart failure: pathophysiology, epidemiology and clinical significance].

Kardiol Pol. 2011;69(11):1181-8.

[Cardiorenal syndrome].

Rev Med Chir Soc Med Nat Iasi. 2011 Jul-Sep;115(3):636-46.

Cardiorenal Syndrome Revisited.

Circulation. 2018 Aug 28;138(9):929-944. doi: 10.1161/CIRCULATIONAHA.117.028814.

Epidemiology of Cardiorenal Syndrome.

Adv Chronic Kidney Dis. 2018 Sep;25(5):391-399. doi: 10.1053/j.ackd.2018.08.009.

[The nephrologist and the role of ultrasound imaging in the diagnosis of cardiorenal syndrome].

G Ital Nefrol. 2012 May-Jun;29(3):321-7.

Cardiorenal syndrome: an evolutionary point of view.

Hypertension. 2012 Sep;60(3):589-95. doi: 10.1161/HYPERTENSIONAHA.111.188706. Epub 2012 Jul 2.

Insulin resistance and heart failure: molecular mechanisms.

Heart Fail Clin. 2012 Oct;8(4):609-17. doi: 10.1016/j.hfc.2012.06.005. Epub 2012 Aug 9.

引用本文的文献

Multiorgan Imaging for Interorgan Crosstalk in Cardiometabolic Diseases.

Circ Res. 2025 May 23;136(11):1454-1475. doi: 10.1161/CIRCRESAHA.125.325517. Epub 2025 May 22.

Cardiovascular-kidney-metabolic Syndrome: a current and urgent concept.

J Bras Nefrol. 2025 Apr-Jun;47(2):e20240277. doi: 10.1590/2175-8239-JBN-2024-0277en.

Joint association of TyG index and LDL-C with all-cause and cardiovascular mortality among patients with cardio-renal-metabolic disease.

Sci Rep. 2025 Feb 18;15(1):5854. doi: 10.1038/s41598-025-87416-7.

eGFR slope as predictor of mortality in heart failure patients.

ESC Heart Fail. 2025 Apr;12(2):1217-1226. doi: 10.1002/ehf2.15128. Epub 2024 Nov 27.

Cardiovascular-kidney-metabolic syndrome - An integrative review.

Prog Cardiovasc Dis. 2024 Nov-Dec;87:26-36. doi: 10.1016/j.pcad.2024.10.012. Epub 2024 Oct 30.

Insulin Resistance, Hyperinsulinemia and Atherosclerosis: Insights into Pathophysiological Aspects and Future Therapeutic Prospects.

Curr Cardiol Rev. 2025;21(1):e1573403X314035. doi: 10.2174/011573403X314035241006185109.

Impact of inhibition of the renin-angiotensin system on early cardiac and renal abnormalities in Sprague Dawley rats fed short-term high fructose plus high salt diet.

Front Nutr. 2024 Aug 22;11:1436958. doi: 10.3389/fnut.2024.1436958. eCollection 2024.

Heart failure: the grim reaper of the cardio-renal-metabolic triad.

ESC Heart Fail. 2024 Aug;11(4):2334-2343. doi: 10.1002/ehf2.14810. Epub 2024 Apr 24.

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin.

Diabetes Ther. 2023 Dec;14(12):1997-2014. doi: 10.1007/s13300-023-01475-5. Epub 2023 Oct 12.

Health Care Costs Associated with the Development and Combination of Cardio-Renal-Metabolic Diseases.

Kidney360. 2023 Oct 1;4(10):1382-1388. doi: 10.34067/KID.0000000000000212. Epub 2023 Jul 18.

本文引用的文献

The Role of Overweight and Obesity in the Cardiorenal Syndrome.

Cardiorenal Med. 2011;1(1):5-12. doi: 10.1159/000322822. Epub 2011 Jan 17.

Therapeutic strategies for heart failure in cardiorenal syndromes.

Am J Kidney Dis. 2010 Oct;56(4):759-73. doi: 10.1053/j.ajkd.2010.04.012. Epub 2010 Jun 16.

Prevalence of chronic kidney disease in the United States.

JAMA. 2007 Nov 7;298(17):2038-47. doi: 10.1001/jama.298.17.2038.

Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease.

Am J Clin Nutr. 2007 Oct;86(4):899-906. doi: 10.1093/ajcn/86.4.899.

Trends in prevalence and outcome of heart failure with preserved ejection fraction.

N Engl J Med. 2006 Jul 20;355(3):251-9. doi: 10.1056/NEJMoa052256.

Prevalence of overweight and obesity in the United States, 1999-2004.

JAMA. 2006 Apr 5;295(13):1549-55. doi: 10.1001/jama.295.13.1549.

Body mass index and risk for end-stage renal disease.

Ann Intern Med. 2006 Jan 3;144(1):21-8. doi: 10.7326/0003-4819-144-1-200601030-00006.

Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease.

Am Heart J. 2005 Jan;149(1):54-60. doi: 10.1016/j.ahj.2004.07.009.

Body mass index and mortality: a meta-analysis based on person-level data from twenty-six observational studies.

Ann Epidemiol. 2005 Feb;15(2):87-97. doi: 10.1016/j.annepidem.2004.05.012.

Obesity and the metabolic syndrome in children and adolescents.

N Engl J Med. 2004 Jun 3;350(23):2362-74. doi: 10.1056/NEJMoa031049.